Details for Patent: 8,257,733

Title:	Methods and compositions for treating proliferative diseases
Abstract:	The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Inventor(s):	Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), De; Tapas (Los Angeles, CA)
Assignee:	Abraxis BioScience, LLC (Los Angeles, CA)
Filing Date:	Oct 06, 2006
Application Number:	11/544,242
Claims:	1. A pharmaceutical composition comprising nanoparticles comprising 17-AAG and an albumin, wherein the nanoparticles comprise 17-AAG coated with the albumin, wherein the average diameter of the nanoparticles in the composition is no greater than about 500 nm. 2. The pharmaceutical composition according to claim 1, wherein the albumin is human serum albumin. 3. The pharmaceutical composition according to claim 2, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 4. The pharmaceutical composition according to claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 5. The pharmaceutical composition according to claim 4, wherein the average diameter of the nanoparticles in the composition is no greater than about 100 nm. 6. The pharmaceutical composition according to claim 1, wherein the weight ratio of the albumin to 17-AAG in the composition is less than about 18:1. 7. The pharmaceutical composition according to claim 6, wherein the weight ratio of the albumin to 17-AAG in the composition is about 2:1 to about 15:1. 8. The pharmaceutical composition according to claim 7, wherein the weight ratio of the albumin to 17-AAG in the composition is about 3:1 to about 12:1. 9. The pharmaceutical composition according to claim 8, wherein the weight ratio of the albumin to 17-AAG in the composition is about 4:1 to about 10:1. 10. The pharmaceutical composition according to claim 1, wherein the composition does not induce significant side effects.